Kivu Bioscience Appoints Dr. Sophia Randolph as Chief Medical Officer

Sophia Randolph, M.D., Ph.D., Chief Medical Officer, Kivu Bioscience • Photo Credit: Kivu Bioscience

SAN MATEO, Calif., October 27, 2025 (WELLNESS INTERVIEWS) – Biotechnology company Kivu Bioscience, which specializes in developing next-generation antibody-drug conjugates (ADCs) for difficult-to-treat cancers, has appointed Sophia Randolph, M.D., Ph.D., as Chief Medical Officer.

Wellness Interviews

♾️

Wellness Interviews ♾️

Randolph brings more than 20 years of experience in oncology drug development, advancing therapeutics from preclinical through late-stage clinical settings. She previously served as Chief Medical Officer at ALX Oncology, where she led the development of biologic therapies targeting the CD47/SIRPalpha checkpoint pathway. Prior to that, she held leadership positions at Pfizer Oncology, contributing to the development of several therapeutics including Xalkori® (crizotinib), Ogsiveo® (nirogacestat), and Ibrance® (palbociclib). Earlier in her career, Randolph worked at Merck, focusing on early-stage oncology programs such as Zolinza® (vorinostat).

“We’re thrilled to welcome Dr. Randolph to Kivu as Chief Medical Officer. Her extensive background in oncology clinical development and deep expertise in advancing innovative therapies across multiple tumor indications will be invaluable as we advance our assets into the clinic. In addition to Sophia’s strong drug development experience, her desire to put patients first and make data driven decisions are core values at Kivu,” said Mohit Trikha, Ph.D., President and Chief Operating Officer of Kivu Bioscience.

“I’m excited to join Kivu at such a pivotal time in its growth. The company’s next-generation ADC platform and the promising preclinical data reflect a thoughtful, patient-centered approach to achieve kinder, gentler and more effective ADC therapies. I look forward to working with the team to translate this science into transformative medicines for patients,” said Randolph.

Randolph holds an A.B. in Biochemistry from Harvard University and both an M.D. and Ph.D. in Cellular and Molecular Biology from the University of Michigan. She completed her oncology fellowship at the University of Washington/Fred Hutchinson Cancer Research Center.

Kivu Bioscience’s proprietary linker-payload technology is designed to enhance the safety and efficacy of ADC therapies by minimizing off-target effects. The company is currently advancing multiple ADC programs toward clinical trials.

For more information, visit www.kivubioscience.com.

Source: Kivu Bioscience